Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Meta's Muse AI agent has surged to the top of U.S. app store charts on rapid early downloads, powering the stock's largest single-day gain in over a year even as Amazon blocks the bot from its shopping site. The community is split between bulls touting a new AI monetization story reinforced by a Wells Fargo target hike and a Shopify agentic-checkout partnership and skeptics calling the move an overbought, hype-driven squeeze that could reverse.

Viking Therapeutics is trending as a sharp intraday reversal on unusually heavy volume fuels trader speculation that the long-awaited VK2735 maintenance trial data guided for release by the end of Q3 2026 is imminent, with some pointing to a possible leak or heavy options activity as confirmation. The community is split between bulls anticipating a strong readout or short squeeze and skeptics calling the move another pump-and-dump, while renewed speculation that Novo Nordisk could pursue a deal adds to the chatter amid its pipeline-driven selloff.

Dogecoin is surging alongside a broad cryptocurrency rally led by Bitcoin, with traders citing heavy short liquidations as price presses against the widely watched $0.10 level. Bulls are celebrating the breakout attempt and voicing meme-coin season hopes, while skeptics warn of sell pressure at that mark and criticize the coin's tokenomics.

AMD is trending after crossing the $1 trillion market-cap milestone for the first time, with shares surging roughly 10% to record highs amid a broader semiconductor rally that traders link to Meta's Muse AI agent and accelerating AI compute demand. Reaction is divided, as bulls celebrate the milestone while bears flag stretched valuations, analyst downgrades, and insider selling as reasons to expect a pullback.

Paramount Skydance is in focus after reportedly reaching a settlement with California and other state attorneys general that removes a major legal obstacle to its Warner Bros. Discovery merger, with reported concessions including expanded annual film-production commitments, an independent editorial board for CBS and CNN, and keeping operations in California. Traders are split over the stock's reversal despite the deal news, with bulls treating the drop as a buying opportunity ahead of a possible closing within weeks and skeptics pointing to sell-the-news behavior, disliked settlement restraints, dilution concerns, and alleged short-selling pressure.

Bitcoin is trending after a sharp rally to its highest levels since January, which traders widely attribute to a massive short squeeze, with hundreds of millions of dollars in short liquidations reported across the crypto market. The community is split between bulls declaring a confirmed new bull market and a break of the downtrend, and skeptics calling the move an overbought trap that could reverse.

Ethereum is rallying sharply as part of a broader crypto market surge, with traders citing heavy short liquidations and the SEC's move toward allowing tokenized stock trading as key drivers. Community sentiment is split between calls that a new bull market is underway and skeptics who see a short squeeze or trap, noting the rally has persisted despite a Fed rate hike and the Senate stalling a crypto market-structure bill.

New Era Energy & Digital is surging after securing a 20-year power purchase agreement with a Vistra affiliate to supply up to 207 MW for Phase 1 of its Texas data center campus. Bulls are calling for a short squeeze and predicting a hyperscaler tenant deal is imminent, while skeptics flag minimal current revenue and speculate a dilutive secondary offering could follow.

Arm shares surged alongside a CPU-led semiconductor rally as traders cited the rapid adoption of Meta's Muse AI agent as evidence that agentic AI workloads will drive sharply higher data-center CPU demand, a read-through tied to Arm's AGI CPU partnership with Meta even though neither company has confirmed Muse runs on Arm silicon. Reaction is split between momentum buyers betting the CPU-demand narrative has further to run and skeptics calling the move overextended amid elevated valuation concerns.

Novo Nordisk shares slid sharply after its Capital Markets Day, where long-term targets including more than five new blockbusters by 2030 failed to reassure investors focused on mid-single-digit growth guidance, Eli Lilly competition, and looming semaglutide patent expirations. The community is split between dip-buyers calling the stock deeply oversold at a low valuation and critics blaming management's execution and communication, with some speculating a major acquisition is needed to restore growth.